In the title pyrrolizidine derivative, C33H26F2N2O2, both pyrrolidine rings of the pyrrolizidine moiety adopt an envelope conformation. The di-fluoro-phenyl group is oriented at an angle of 54.3 (1)° with respect to the oxindole moiety. The crystal packing features an N-H⋯O hydrogen bond, which forms an R 2 (2)(8) motif, and a C-H⋯O inter-action, which generates a C(8) chain along [010]. In addition, this chain structure is stabilized by C-H⋯π inter-actions. In one of the pyrrolidine rings, the methyl-ene group forming the flap of an envelope and the H atoms of the adjacent methyl-ene groups are disordered over two sets of sites, with site-occupancy factors of 0.571 (4) and 0.429 (4).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571355 | PMC |
| http://dx.doi.org/10.1107/S2056989015012931 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS).
AIDS Res Ther
December 2024
Veterans Affairs (VA) Connecticut Healthcare System Cooperative Studies Program Clinical Epidemiology Research Center (CSP-CERC), 950 Campbell Avenue, West Haven, CT, 06516-2770, USA.
Background: Real-world data on treatment patterns and clinical outcomes for newer drugs, including integrase strand transfer inhibitors, among older people with human immunodeficiency virus (PWH) are limited.
Methods: This cohort study included PWH enrolled in the Veterans Aging Cohort Study (VACS) who were prescribed a standard 3-drug antiretroviral therapy (ART) regimen containing dolutegravir (DTG), bictegravir (BIC), cobicistat boosted elvitegravir (EVG), raltegravir (RAL), or darunavir/ritonavir (DRV) plus 2 nucleoside reverse transcriptase inhibitors between January 1, 2014, and March 31, 2020, and who were ≥50 years at regimen initiation. The association between regimen and virologic effectiveness or discontinuation was assessed using logistic regression models with inverse probability of treatment weights.
Ethyl (2,3,4)-1-ethyl-2-(furan-2-yl)-4-hy-droxy-5-oxopyrrolidine-3-carboxyl-ate.
IUCrdata
November 2024
EaStCHEM School of Chemistry, University of St Andrews, St Andrews, Fife KY16 9ST, United Kingdom.
The title racemic oxopyrrolidine compound, CHNO, contains three stereogenic centres and crystallizes with two mol-ecules in the asymmetric unit. The five-membered pyrrolidine rings in both mol-ecules exhibit envelope conformations. The -ethyl group of one of the mol-ecules is disordered over two sets of sites in a 0.
View Article and Find Full Text PDFReal-world experience in treatment of donor-derived Hepatitis C virus in kidney transplant recipients with delayed initiation, shortened course glecaprevir/pibrentasvir versus standard of care.
Transpl Infect Dis
December 2024
Department of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
Background: There is limited literature describing the real-world practice of delayed initiation and shortened duration direct-acting antiviral (DAA) in kidney transplant recipients. We compared Hepatitis C virus (HCV) cure rates among kidney transplant recipients who received an HCV nucleic acid test positive (NAT +) kidney and were treated with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks or glecaprevir/pibrentasvir (G/P) for 8 weeks, a duration that is 4 weeks shorter than the guideline recommendation for treatment delay beyond 1-week post-transplant.
Methods: Retrospective study of HCV-negative adult patients who received a kidney transplant from an HCV NAT+ donor between April 2019 and April 2022 treated with either SOF/VEL for 12 weeks or G/P for 8 weeks.
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review.
Expert Opin Pharmacother
August 2024
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Introduction: Pharmacotherapy against hepatitis C virus (HCV) infection has tremendously improved since the advent of interferon (IFN)-free direct-acting antivirals (DAAs). Additionally, fixed-dose pangenotypic DAAs, which are safe, potent, easy for use, and can cover a wide spectrum of patients, have been recommended by professional guidelines for DAA-naïve and DAA-experienced patients with HCV.
Areas Covered: We review the pharmacokinetics, pharmacodynamics, and potential drug-drug interactions (DDIs) of fixed-dose pangenotypic DAA regimens, including glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/VEL), and sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX).
Is there a role for biogenic amine receptors in mediating β-phenylethylamine and RO5256390-induced vascular contraction?
Eur J Pharmacol
October 2024
Division of Pharmacology, School of Pharmacy, Cardiff University, Cardiff, United Kingdom.
Article Synopsis
- Trace amines can cause blood vessel constriction without involving noradrenaline, and the exact mechanism behind this is still unclear.
- The study tested the effects of β-phenylethylamine (β-PEA) and a TAAR1-selective agonist on blood vessel constriction in rat aortic rings and mesenteric arteries.
- Results showed that vasoconstriction in aortic rings was not affected by common biogenic amine antagonists, suggesting TAAR1 is likely responsible for the response to trace amines.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!